13 unknown. 13 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Unknown 13 |
| Phase 2 | 3 | Unknown 3 |
Follow Bladder Cancer: new trials by email Literature Review of Bladder Cancer trials Research Report on Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC) 9MW2821 - Bladder Cancer | Phase 1 | Unknown | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 30 | 2024-04-22 | 2024-08-13 |
| Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients Herpes virus T3011 injection - Bladder Cancer | Phase 1 | Unknown | Fudan University | 20 | 2023-09-21 | 2024-05-23 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers APL-1202 and APL-1501 (Single ascending dose), APL-1202 and APL-1501 (Multiple Ascending dose) - Bladder Cancer | Phase 1 | Unknown | Jiangsu Yahong Meditech Co., Ltd aka Asieris | 48 | 2023-09-09 | 2023-09-13 |
| The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1 Intravenous injection of P-IL-2, P-IL-2 plus Anti-PD-1 Monoclonal Antibody - Esophagus Cancer, Bladder Cancer | Phase 1 | Unknown | Zhejiang University | 10 | 2023-05-23 | 2024-02-13 |
| Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells cytokine-induced killer cells, Standard treatment according to the Clinical protocols - Bladder Cancer, Renal Cancer | Phase 1 / Phase 2 | Unknown | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | 20 | 2022-03-01 | 2022-01-14 |
| Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration - Carcinoma, Melanoma | Phase 1 | Unknown | Sichuan University | 60 | 2022-03-01 | 2022-02-11 |
| Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine Catumaxomab - Bladder Cancer | Phase 1 / Phase 2 | Unknown | LintonPharm Co.,Ltd. | 161 | 2021-11-23 | 2023-02-13 |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors CT-0508, Pembrolizumab - HER2-positive, Adenocarcinoma | Phase 1 | Unknown | Carisma Therapeutics Inc | 48 | 2021-02-02 | 2024-12-18 |
| MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour MRx0518 Capsules, MRx0518/placebo Capsules - Melanoma, Breast Cancer | Phase 1 | Unknown | Imperial College London | 120 | 2019-04-10 | 2022-08-11 |
| A Study of BCD-135 in Patients With Advanced Solid Tumors BCD-135 - Melanoma, NSCLC | Phase 1 | Unknown | Biocad | 30 | 2017-10-31 | 2018-03-13 |
| A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors D-CIK and anti-PD-1 antibody - Hepatocellular Carcinoma, Renal Cell Carcinoma | Phase 1 / Phase 2 | Unknown | Sun Yat-sen University | 50 | 2016-07-01 | 2016-09-01 |
| A Study for Treatment of Superficial Bladder Cancer Using OGX-427 OGX-427 - Bladder Cancer | Phase 1 | Unknown | Vancouver Coastal Health | 36 | 2009-07-01 | 2012-02-13 |
| 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder diagnostic cystoscopy, diffusion-weighted magnetic resonance imaging, implanted fiducial-based imaging - Bladder Cancer | Phase 1 | Unknown | Institute of Cancer Research, United Kingdom | 60 | 2009-05-01 | 2013-08-26 |
Urinary Bladder Neoplasms (13) · Breast Neoplasms (3) · Colorectal Neoplasms (3) · Melanoma (3) · Neoplasms (3) · Ovarian Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Head and Neck Neoplasms (2) · Kidney Neoplasms (2) · Prostatic Neoplasms (2) · Small Cell Lung Carcinoma (2) · Adenocarcinoma (1) · Bile Duct Neoplasms (1)
Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Male Urogenital Diseases (13) · Neoplasms by Site (13) · Urinary Bladder Diseases (13) · Urogenital Diseases (13) · Urogenital Neoplasms (13) · Urologic Diseases (13) · Urologic Neoplasms (13) · Neoplasms (10) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Carcinoma (4)
Radiotherapy, Conformal (1) · Radiotherapy, Image-Guided (1) · Serotonin Plasma Membrane Transport Proteins (1) · apatorsen (1) · catumaxomab (1) · pembrolizumab (1)
Biocad (1) · Carisma Therapeutics Inc (1) · Fudan University (1) · Imperial College London (1) · Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus (1) · Institute of Cancer Research, United Kingdom (1) · Jiangsu Yahong Meditech Co., Ltd aka Asieris (1) · LintonPharm Co.,Ltd. (1) · Sichuan University (1) · Sun Yat-sen University (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · Vancouver Coastal Health (1) · Zhejiang University (1)
China (6) · United Kingdom (2) · Australia (1) · Belarus (1) · Canada (1) · Russia (1) · United States (1)
Alan I So, MD, FRCSC (1) · Alexander Prokhorov, Dr (1) · Andrei Hancharou (1) · Dingwei Ye, Doctor (1) · Dr Jonathan Krell (1) · Jeanett Wetzel (1) · Ji-Yan Liu (1) · Robert A. Huddart, MD (1) · Svetlana Odintsova, MD (1) · Yi-Xin Zeng, Ph.D. (1)
PMID 22461641, PMID 24668644, PMID 25747273, PMID 26228759, PMID 26871284, PMID 36441083, PMID 39069239, PMID 39726590, PMID 39920391